Insmed reported $17.81B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Cytokinetics USD 11.55B 3.36B Jun/2026
DBV Technologies USD 1.23B 327M Mar/2026
Gilead Sciences USD 156.86B 16.13B Jun/2026
Heron Therapeutics USD 238M 7M Dec/2025
Insmed USD 23.11B 12.19B Jun/2026
Novartis USD 288.26B 25.18B Mar/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026